LYEL

+ Watchlist + Portfolio

Lyell Immunopharma, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.41
52-Week Range: $9.21 – $45.00
Market Cap: $226.92M
P/E (TTM): —
EPS (TTM): -12.86
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.93
PEG Ratio: —
Return on Equity: -93.28%
Return on Assets: -34.18%
Gross Margin: 100.00%
Operating Margin: -1183425.00%
Profit Margin: 0.00%
Current Ratio: 5.36
Debt/Equity: 0.20
Total Debt: $46.60M
Free Cash Flow: $-72.81M
Revenue Growth: -50.00%
Earnings Growth: —
Enterprise Value: $69.41M

LYEL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$84.68M	$130.00K	$61.00K	$36.00K
Research & Development	$159.19M	$182.94M	$171.60M	$158.68M
Selling, General & Admin	$117.31M	$66.98M	$52.04M	$45.13M
Operating Expenses	$271.74M	$247.14M	$220.34M	$201.66M
Operating Income	-$187.06M	-$247.01M	-$220.27M	-$201.63M
EBITDA	-$169.04M	-$226.76M	-$200.64M	-$190.09M
Pretax Income	-$183.12M	-$234.63M	-$342.99M	-$274.45M
Net Income	-$183.12M	-$234.63M	-$342.99M	-$274.45M
Diluted EPS	-14.80	-18.70	-23.26	-12.91
Diluted Shares	12.35M	12.55M	14.74M	21.25M

LYEL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$123.55M	$145.65M	$105.60M	$60.18M
Current Assets	$651.29M	$554.69M	$379.59M	$260.94M
Total Assets	$937.56M	$750.03M	$490.86M	$340.05M
Current Liabilities	$37.03M	$34.52M	$53.79M	$49.41M
Total Debt	$67.70M	$63.17M	$58.97M	$50.99M
Total Liabilities	$104.31M	$95.08M	$108.03M	$91.85M
Retained Earnings	-$767.48M	-$1.00B	-$1.35B	-$1.62B
Shareholders' Equity	$833.25M	$654.95M	$382.82M	$248.20M
Working Capital	$614.27M	$520.17M	$325.81M	$211.53M

LYEL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$169.56M	-$163.69M	-$162.39M	-$150.02M
Capital Expenditure	-$24.28M	-$2.69M	-$464.00K	-$780.00K
Free Cash Flow	-$193.83M	-$166.38M	-$162.86M	-$150.80M
Depreciation & Amortisation	$18.02M	$20.25M	$19.63M	$11.54M
Stock-Based Compensation	$81.92M	$47.08M	$33.14M	$41.83M
Investing Cash Flow	-$11.54M	$184.05M	$122.42M	$54.10M
Financing Cash Flow	$10.63M	$1.74M	$1.33M	$50.41M
Share Repurchases	$0.00	—	—	—
Net Change in Cash	-$170.46M	$22.10M	-$38.64M	-$45.52M

LYEL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$7.00K	$8.00K	$15.00K	$6.00K	$2.00K	$4.00K
Research & Development	$43.45M	$34.86M	$28.17M	$52.20M	$36.60M	$39.52M
Selling, General & Admin	$14.05M	$9.79M	$10.69M	$10.62M	$9.55M	$9.58M
Operating Expenses	$57.37M	$45.70M	$37.27M	$61.32M	$44.26M	$47.34M
Operating Income	-$57.37M	-$45.70M	-$37.25M	-$61.31M	-$44.26M	-$47.34M
EBITDA	-$53.93M	-$42.56M	-$34.69M	-$58.91M	-$41.93M	-$45.12M
Pretax Income	-$52.20M	-$42.68M	-$38.85M	-$140.72M	-$24.15M	-$44.76M
Net Income	-$52.20M	-$42.68M	-$38.85M	-$140.72M	-$24.15M	-$44.76M
Diluted EPS	-3.54	-2.89	-2.13	-6.62	-1.10	-1.92
Diluted Shares	14.76M	14.79M	18.27M	21.25M	21.88M	23.36M

LYEL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$120.33M	$98.80M	$123.58M	$60.18M	$90.77M	$72.98M
Current Assets	$309.18M	$282.21M	$328.20M	$260.94M	$267.30M	$213.54M
Total Assets	$429.80M	$385.45M	$407.96M	$340.05M	$350.63M	$311.15M
Current Liabilities	$41.28M	$36.90M	$31.88M	$49.41M	$36.95M	$39.87M
Total Debt	$48.85M	$46.60M	$44.28M	$50.99M	$39.49M	$36.93M
Total Liabilities	$93.28M	$86.53M	$78.84M	$91.85M	$76.96M	$77.34M
Retained Earnings	-$1.40B	-$1.44B	-$1.48B	-$1.62B	-$1.64B	-$1.69B
Shareholders' Equity	$336.52M	$298.92M	$329.12M	$248.20M	$273.67M	$233.81M
Working Capital	$267.89M	$245.31M	$296.32M	$211.53M	$230.36M	$173.67M

LYEL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$54.74M	-$34.46M	-$28.58M	-$32.25M	-$38.51M	-$33.92M
Capital Expenditure	-$246.00K	-$168.00K	-$62.00K	-$304.00K	-$89.00K	-$256.00K
Free Cash Flow	-$54.98M	-$34.63M	-$28.64M	-$32.55M	-$38.60M	-$34.18M
Depreciation & Amortisation	$3.44M	$3.13M	$2.57M	$2.40M	$2.33M	$2.22M
Stock-Based Compensation	$6.02M	$5.00M	$5.23M	$25.57M	$4.29M	$4.53M
Investing Cash Flow	$69.47M	$12.65M	$3.35M	-$31.36M	$17.38M	$15.62M
Financing Cash Flow	$1.00K	$183.00K	$50.00M	$222.00K	$51.72M	$522.00K
Net Change in Cash	$14.73M	-$21.63M	$24.77M	-$63.39M	$30.59M	-$17.78M

Market Snapshot

About

Lyell Immunopharma, Inc. is a T-cell reprogramming company developing cell therapies for solid tumors. The company focuses on addressing T-cell exhaustion and enhancing the persistence and functionality of engineered T-cells for cancer treatment. Lyell combines synthetic biology and genetic reprogramming techniques to create next-generation adoptive cell therapies.